Header Logo

MARK TITUS

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T, Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543. PMID: 37930121; PMCID: PMC10718063.
      Citations:    Translation:HumansAnimalsCells
    2. Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate Cancer. Mol Cancer Res. 2023 01 03; 21(1):51-61. PMID: 36112348; PMCID: PMC9812897.
      Citations:    
    3. Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):751-758. PMID: 36100698.
      Citations:    
    4. Basu HS, Wilganowski N, Robertson S, Reuben JM, Cohen EN, Zurita A, Ramachandran S, Xiao LC, Titus M, Wilding G. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate. 2021 09; 81(12):799-811. PMID: 34170017; PMCID: PMC10921976.
      Citations:    Fields:    Translation:HumansCells
    5. Shen S, Li J, Huo S, Ma M, Zhu X, Rasam S, Duan X, Qu M, Titus MA, Qu J. Parallel, High-Quality Proteomic and Targeted Metabolomic Quantification Using Laser Capture Microdissected Tissues. Anal Chem. 2021 06 29; 93(25):8711-8718. PMID: 34110778; PMCID: PMC10640922.
      Citations: 2     Fields:    Translation:Humans
    6. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999. PMID: 31941830.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol. 2019 02; 21(1):86-94. PMID: 29748904; PMCID: PMC6230314.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    8. Sabnis NG, Miller A, Titus MA, Huss WJ. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. Mol Cancer Res. 2017 02; 15(2):128-140. PMID: 27856956; PMCID: PMC5290130.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    9. Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep. 2016 10 17; 6:35354. PMID: 27748439; PMCID: PMC5066251.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    10. Zhang B, Kwon OJ, Henry G, Malewska A, Wei X, Zhang L, Brinkley W, Zhang Y, Castro PD, Titus M, Chen R, Sayeeduddin M, Raj GV, Mauck R, Roehrborn C, Creighton CJ, Strand DW, Ittmann MM, Xin L. Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Mol Cell. 2016 09 15; 63(6):976-89. PMID: 27594448; PMCID: PMC5026614.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    11. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60. PMID: 24882673; PMCID: PMC4247811.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    12. Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL. Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate. 2014 May; 74(7):722-31. PMID: 24847527; PMCID: PMC4335642.
      Citations: 9     Fields:    Translation:Humans
    13. Thapar R, Titus MA. Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer. Curr Metabolomics. 2014 Apr; 2(1):53-69. PMID: 25632377; PMCID: PMC4306198.
      Citations: 12     
    14. Krishnan N, Titus MA, Thapar R. The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins. PLoS One. 2014; 9(1):e85427. PMID: 24416409; PMCID: PMC3887067.
      Citations: 19     Fields:    Translation:HumansCells
    15. Titus MA, Li Y, Kozyreva OG, Maher V, Godoy A, Smith GJ, Mohler JL. 5a-reductase type 3 enzyme in benign and malignant prostate. Prostate. 2014 Feb; 74(3):235-49. PMID: 24150795; PMCID: PMC3992828.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    16. Tan JA, Bai S, Grossman G, Titus MA, Harris Ford O, Pop EA, Smith GJ, Mohler JL, Wilson EM, French FS. Mechanism of androgen receptor corepression by CK?BP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Mol Cell Endocrinol. 2014 Jan 25; 382(1):302-313. PMID: 24103312; PMCID: PMC3880566.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    17. Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One. 2012; 7(1):e30192. PMID: 22272301; PMCID: PMC3260230.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    18. Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011 Sep 15; 17(18):5844-9. PMID: 21705451; PMCID: PMC3177006.
      Citations: 32     Fields:    Translation:HumansCells
    19. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011 Feb 15; 71(4):1486-96. PMID: 21303972; PMCID: PMC3075600.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    20. Titus M, Tomer KB. Androgen quantitation in prostate cancer tissue using liquid chromatography tandem mass spectrometry. Methods Mol Biol. 2011; 776:47-57. PMID: 21796519.
      Citations: 6     Fields:    Translation:Humans
    21. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus MA, Mohler JL. 5a-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011 Jul; 71(10):1033-46. PMID: 21557268; PMCID: PMC4295561.
      Citations: 38     Fields:    Translation:HumansCells
    22. Titus MA, Mohler JL, Tomer KB, Lih FB. Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Anal Chem. 2010 Jul 15; 82(14):6000-7. PMID: 20560527; PMCID: PMC2928567.
      Citations: 9     Fields:    Translation:Humans
    23. Titus MA, Tan JA, Gregory CW, Ford OH, Subramanian RR, Fu H, Wilson EM, Mohler JL, French FS. 14-3-3{eta} Amplifies Androgen Receptor Actions in Prostate Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7571-7581. PMID: 19996220; PMCID: PMC2795092.
      Citations: 7     Fields:    
    24. Singh SS, Li Y, Ford OH, Wrzosek CS, Mehedint DC, Titus MA, Mohler JL. Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer. Transl Oncol. 2008 Sep; 1(3):153-7. PMID: 18795150; PMCID: PMC2533144.
      Citations: 11     
    25. Yang Q, Titus MA, Fung KM, Lin HK. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. J Cell Biochem. 2008 Aug 01; 104(5):1612-24. PMID: 18320593.
      Citations: 6     Fields:    Translation:HumansCells
    26. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4653-7. PMID: 16000557.
      Citations: 200     Fields:    Translation:Humans
    27. Titus MA, Gregory CW, Ford OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005 Jun 15; 11(12):4365-71. PMID: 15958619.
      Citations: 60     Fields:    Translation:HumansCells
    28. 5α-reductase type 3 enzyme in benign and malignant prostate. Prostate. 74:235-249.
    29. 5α-reductase isozymes in castration-recurrent prostate cancer. 175-185.
    30. Thioredoxin reductase 1 expression and castration-recurrent growth of prostate cancer. Translational Oncology. 1:153-157.
    31. Tissue levels of androgens in castration-recurrent prostate cancer. 553-568.
    32. Intracrine synthesis of androgens by prostate cancer in response to androgen deprivation therapy. 193-218.
    33. 14-3-3η amplifies androgen receptor actions in prostate cancer. Clinical Cancer Research. 15:7571-7581.
    34. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports. 6.
    35. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 7:46321-46334.
    36. Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Molecular Cell. 63:976-989.
    37. Editorial Comment. Journal of Urology. 178:1288-1289.
    TITUS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (179)
    Explore
    _
    Co-Authors (26)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _